Alnylam Pharmaceuticals (ALNY) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $266.11 +0.61%
EPS Growth %: -39.0%
Financial Fact:
Total operating expenses: 101.16M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -39.0%
Financial Fact:
Total operating expenses: 101.16M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q2 EPS of ($0.33), $0.03 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $19.97 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- Guidewire Software (GWRE) Tops Q4 EPS by 6c; Offers Guidance
- BMO Capital on Alnylam Pharmaceuticals (ALNY): 'Strong ATTR Outlook With Limited Readthrough From Eplontersen'
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
